AAAAI

AAAAI 2026: Drug allergy labels often unverified in children with immune disorders

March 4, 2026

Findings presented at the 2026 AAAAI Annual Meeting highlight that drug allergy labels (DALs) are widespread yet seldom assessed in children with primary immunodeficiencies. In a review of 219 patients, nearly half carried at least one DAL, and 43% of all labels involved antibiotics. However, only 18.9% of labeled children received formal evaluation, which led to delabeling in 17 of 20 cases. Researchers warn that unevaluated DALs may restrict first-line antibiotic use and contribute to poorer outcomes, including longer hospital stays and higher readmission rates. The study underscores the clinical value of allergy assessment to optimize antimicrobial therapy in this high‑risk population.

Source:

(2026, February 10). American Academy of Allergy, Asthma, & Immunology. Drug Allergy Labels Rarely Evaluated for Children with Primary Immunodeficiencies [News release]. https://www.aaaai.org/about/news/news/2026/drug